Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Monster Beverage Corp (MNST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Monster Beverage Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $222.01 (market cap $29.60B), while Monster Beverage Corp trades at $45.99 (market cap $89.20B). The key difference: Monster Beverage Corp is far larger — about 3× Alnylam Pharmaceuticals, Inc.'s market cap, and Monster Beverage Corp is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | MNST | |
|---|---|---|
Market Cap | $29.60B | $89.20B |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $49.97 |
52-Week Low | $205.48 | $30.86 |
Enterprise Value | $27.56B | $87.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Monster Beverage (MNST) trades at $45.895, up 0.45% with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $8.29B and net income of $1.91B, achieving a 23.08% net margin. Recent Q2 2026 results beat expectations with $0.60 EPS versus $0.59 expected, driven by international growth. A 2-for-1 stock split occurred on August 11, 2026, while analyst consensus remains positive with 51% buy ratings and a $51.14 price target.
MNST's outlook is supported by robust earnings growth and global expansion, but elevated valuation ratios (P/E 42.16, P/S 9.75) pose risks. Competitive pressures in the energy drink sector and macroeconomic sensitivity could challenge margins. Institutional sentiment is cautiously optimistic, with upside potential to the consensus target representing 11% gain from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →
